Psychedelic Stocks Archives - Page 58 of 61

FridayFeb 04, 2022 2:48 pm

Oregon Legislators File Bill to Ensure Psilocybin Equity

Legislators in the state of Oregon have introduced a bicameral initiative that will establish a 15-member group that will focus on psilocybin health equity. The task force will be made up of representatives of the indigenous community, individuals with experience with psychedelic treatment, regulators involved in psilocybin reform implementation and legislators. This comes as the state prepares to implement its first legal psilocybin services program. The measure, which was introduced by Rep. Wlnsvey Campos and Sen. Lawrence Spence, stipulates that the task force will be responsible for ensuring accessibility and equity in the state’s developing psilocybin services. The group will…

ThursdayFeb 03, 2022 2:57 pm

Colorado Campaigners File Modified Measures to Establish Psychedelic Healing Centers

Activists in the state of Colorado recently filed amended versions of two ballot measures that would establish licensed healing centers where individuals can use psilocybin for therapeutic purposes and legalize psilocybin. Legislators in the state also introduced a separate measure requiring that research into the effectiveness of plant-based psychedelic substances be conducted. The two 2022 ballot initiatives were filed by Veronica Perez, an entrepreneur, and Kevin Matthews, the campaign manager behind the 2019 vote to locally decriminalize psilocybin in Denver. The measures are similar to earlier versions activists filed with the office of the secretary of state in December, excluding…

WednesdayFeb 02, 2022 2:24 pm

Study Finds Psilocybin Can Be Safely Administered Without Adverse Effects

A new study conducted by researchers at the Institute of Psychiatry, Psychology & Neuroscience has found that psilocybin can be administered safely to six participants at the same time, at doses of either 25 mg or 10 mg. Psilocybin is a naturally occurring hallucinogenic compound found in certain mushrooms that grow in Mexico, South America, Europe and the United States. The research has demonstrated the viability and safety of psilocybin for use in controlled settings in combination with therapy as a possible treatment for various mental health disorders, including post-traumatic stress disorder and treatment-resistant depression. The treatments currently used to…

TuesdayFeb 01, 2022 2:19 pm

Training Gets Underway for Crucial Psychedelic Clinical Trial

Recently, psychotherapist training for a psychedelic clinical trial that is being led by Beckley Psytech began. This comes as interest in psychedelic substances and the properties and benefits they possess increases in America as well as the United Kingdom. Beckley Psytech specializes in addressing psychiatric and neurological disorders through new applications for psychedelic drugs. The pioneering phase 2 clinical trial will explore 5-MeO-DMT assisted psychotherapy in the management of treatment-resistant depression. Psychedelic-assisted psychotherapy refers to the therapeutic process entailing the administration of a psychedelic drug alongside traditional talk-therapy sessions. Prior clinical trials have demonstrated that psychedelic-assisted psychotherapy improves clinical symptoms…

MondayJan 31, 2022 3:44 pm

Psychedelics Reform Movement Here to Stay, Says NIDA Boss

During a National Institutes for Health workshop on the use of psychedelic drugs as therapeutics, Dr. Nora Volkow, director of the National Institute on Drug Abuse (“NIDA”), suggested that the psychedelics reform movement was here to stay. Volkow stated that individuals would soon start using the substances with or without approval from the FDA, given the attention the drugs had attracted. The director added that the moment was a good opportunity for her as well as her colleagues to change their approach to psychedelic drugs, which have demonstrated their effectiveness in treating various indications, including alcohol use disorder, anxiety, depression…

FridayJan 28, 2022 1:53 pm

Utah Bill Will Establish Task Force to Research Medical Use of Psychedelics

Representative Brady Brammer recently filed a measure that would establish a task force to investigate whether psychedelic substances should be used as a treatment option for post-traumatic stress disorder and other mental health conditions. In an interview last week, the Utah representative stated that while he hadn’t explored psychedelics personally, he empathized with individuals who were struggling with mental illnesses. While the measure in question, House Bill 167, doesn’t legalize psychedelic substances, it does request experts in the Huntsman Mental Health Institute and others involved in the psychedelic field to analyze research and the scientific evidence on psychedelics and give…

ThursdayJan 27, 2022 12:18 pm

Pennsylvania May Legalize Psychedelics Faster Than It Did Cannabis

Recently, Pennsylvania state Reps Jennifer O’Mara and Tracy Pennycuick introduced the Public Health Benefits of Psilocybin Act to the House. The measure, dubbed House Bill 1959, will allow studies to be conducted on the use of psilocybin as a treatment of various mental health conditions, from substance-abuse and eating disorders to suicidal ideation and post-traumatic stress disorder, in the state. The measure notes that priority will be given to studies with retired first responders and veterans. Bradford Bitting, husband to O’Mara, has served two combat tours in Afghanistan, which earned him two Purple Hearts. Bitting suffers from post-traumatic stress disorder.…

WednesdayJan 26, 2022 11:47 am

Study Shows That Ketamine May Effectively Treat Alcohol Use Disorder

Awakn Life Sciences recently announced results from its double-blind, placebo-controlled trial, which is exploring the effectiveness of ketamine-assisted therapy in treating alcohol use disorder. The results show promise, offering hope for millions of individuals around the globe who suffer from alcohol addiction. The trial comprised of 96 patients suffering from severe alcohol use disorder who were randomly divided into four groups. The first group received three ketamine IV infusions and proprietary, manualized therapy. The second group received proprietary, manualized therapy and the placebo, which was three saline infusions. The third group received alcohol education and ketamine infusions, while the fourth…

TuesdayJan 25, 2022 1:58 pm

New Measures Filed in Virginia Could Decriminalize Psychedelics

Last week, legislators in the state of Virginia introduced new measures to decriminalize the possession of psychedelic substances. The bills in the Senate and the House of Delegates are almost identical, except that the proposal in the latter covers a number of psychedelic substances while the first one only calls for a reduction in the penalties imposed for psilocin and psilocybin possession. The measure introduced in the House would amend the Virginia’s drug statute by making the possession of psilocin, psilocybin, ibogaine or peyote by individuals aged 21 and above a civil penalty punishable by a $100 fine. The possession…

MondayJan 24, 2022 10:49 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to Launch Specialized Psychedelic Program in Canada

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) announced that it would be launching a special access psychedelic-assisted psychotherapy program, called the Special Access Support and Supply Program. The program will be available to patients who require alternative treatment modalities in Canada. The country recently added psilocybin and MDMA to its Special Access Program. Mydecine’s objective is to change the way in which mental health conditions and addiction disorders are treated. The company will provide support services through the program, which will play an important role in fulfilling the company’s mission statement. This is in addition to offering specialized psychedelic…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks